307 related articles for article (PubMed ID: 34400640)
1. Large-scale and high-resolution mass spectrometry-based proteomics profiling defines molecular subtypes of esophageal cancer for therapeutic targeting.
Liu W; Xie L; He YH; Wu ZY; Liu LX; Bai XF; Deng DX; Xu XE; Liao LD; Lin W; Heng JH; Xu X; Peng L; Huang QF; Li CY; Zhang ZD; Wang W; Zhang GR; Gao X; Wang SH; Li CQ; Xu LY; Liu W; Li EM
Nat Commun; 2021 Aug; 12(1):4961. PubMed ID: 34400640
[TBL] [Abstract][Full Text] [Related]
2. Kinome Profiling of Primary Endometrial Tumors Using Multiplexed Inhibitor Beads and Mass Spectrometry Identifies SRPK1 as Candidate Therapeutic Target.
Kurimchak AM; Kumar V; Herrera-Montávez C; Johnson KJ; Srivastava N; Davarajan K; Peri S; Cai KQ; Mantia-Smaldone GM; Duncan JS
Mol Cell Proteomics; 2020 Dec; 19(12):2068-2090. PubMed ID: 32994315
[TBL] [Abstract][Full Text] [Related]
3. Target Score-A Proteomics Data Selection Tool Applied to Esophageal Cancer Identifies GLUT1-Sialyl Tn Glycoforms as Biomarkers of Cancer Aggressiveness.
Cotton S; Ferreira D; Soares J; Peixoto A; Relvas-Santos M; Azevedo R; Piairo P; Diéguez L; Palmeira C; Lima L; Silva AMN; Lara Santos L; Ferreira JA
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562270
[TBL] [Abstract][Full Text] [Related]
4. Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target.
Urick ME; Bell DW
Cancer Med; 2020 Jun; 9(11):3863-3874. PubMed ID: 32248654
[TBL] [Abstract][Full Text] [Related]
5. Distinct esophageal adenocarcinoma molecular subtype has subtype-specific gene expression and mutation patterns.
Guo X; Tang Y; Zhu W
BMC Genomics; 2018 Oct; 19(1):769. PubMed ID: 30355311
[TBL] [Abstract][Full Text] [Related]
6. Tissue-derived exosome proteomics identifies promising diagnostic biomarkers for esophageal cancer.
Rao D; Lu H; Wang X; Lai Z; Zhang J; Tang Z
Elife; 2023 Nov; 12():. PubMed ID: 37966470
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
8. Mass Spectrometry for Biomarkers Discovery in Esophageal Squamous Cell Carcinoma.
Islam F; Gopalan V; Lam AK
Methods Mol Biol; 2020; 2129():259-268. PubMed ID: 32056183
[TBL] [Abstract][Full Text] [Related]
9. High-throughput proteomics of breast cancer subtypes: Biological characterization and multiple candidate biomarker panels to patients' stratification.
Azevedo ALK; Gomig THB; Batista M; Marchini FK; Spautz CC; Rabinovich I; Sebastião APM; Oliveira JC; Gradia DF; Cavalli IJ; Ribeiro EMSF
J Proteomics; 2023 Aug; 285():104955. PubMed ID: 37390896
[TBL] [Abstract][Full Text] [Related]
10. Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma.
Lai J; Xu T; Yang H
BMC Cancer; 2022 Mar; 22(1):325. PubMed ID: 35337291
[TBL] [Abstract][Full Text] [Related]
11. Identification of prognostic miRNA biomarkers for esophageal cancer based on The Cancer Genome Atlas and Gene Expression Omnibus.
Xue J; Jia E; Ren N; Xin H
Medicine (Baltimore); 2021 Feb; 100(7):e24832. PubMed ID: 33607850
[TBL] [Abstract][Full Text] [Related]
12. Proteomic Analysis of Human Esophageal Cancer Using Tandem Mass Tag Quantifications.
Sun S; Zhang H; Wang Y; Gao J; Zhou S; Li Y; Han S; Li X; Li J
Biomed Res Int; 2020; 2020():5849323. PubMed ID: 32832552
[TBL] [Abstract][Full Text] [Related]
13. Construction of a novel necroptosis-related lncRNA signature for prognosis prediction in esophageal cancer.
Liu Y; Hao H; Kang L; Zheng G; Guo X; Li B; Zhao H; Hao H
BMC Gastroenterol; 2022 Jul; 22(1):345. PubMed ID: 35840890
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of sine oculis homeobox homolog 3 is associated with proliferation, invasion, migration, as well as poor prognosis of esophageal cancer.
Du J
Anticancer Drugs; 2019 Jul; 30(6):596-603. PubMed ID: 30672777
[TBL] [Abstract][Full Text] [Related]
15. lncRNA CCAT2 promotes radiotherapy resistance for human esophageal carcinoma cells via the miR‑145/p70S6K1 and p53 pathway.
Wang M; Wang L; He X; Zhang J; Zhu Z; Zhang M; Li X
Int J Oncol; 2020 Jan; 56(1):327-336. PubMed ID: 31789385
[TBL] [Abstract][Full Text] [Related]
16. SWATH-based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours.
López-Sánchez LM; Jiménez-Izquierdo R; Peñarando J; Mena R; Guil-Luna S; Toledano M; Conde F; Villar C; Díaz C; Ortea I; De la Haba-Rodríguez JR; Aranda E; Rodríguez-Ariza A
J Cell Mol Med; 2019 Dec; 23(12):8219-8232. PubMed ID: 31560832
[TBL] [Abstract][Full Text] [Related]
17. A Risk Model Based on Immune-Related Genes Predicts Prognosis and Characterizes the Immune Landscape in Esophageal Cancer.
Xie Y; Fu R; Xiao Z; Li G
Pathol Oncol Res; 2022; 28():1610030. PubMed ID: 35356506
[TBL] [Abstract][Full Text] [Related]
18. Serum-based six-miRNA signature as a potential marker for EC diagnosis: Comparison with TCGA miRNAseq dataset and identification of miRNA-mRNA target pairs by integrated analysis of TCGA miRNAseq and RNAseq datasets.
Sharma P; Saraya A; Sharma R
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e289-e301. PubMed ID: 29380534
[TBL] [Abstract][Full Text] [Related]
19. Integrative stemness characteristics associated with prognosis and the immune microenvironment in esophageal cancer.
Yi L; Huang P; Zou X; Guo L; Gu Y; Wen C; Wu G
Pharmacol Res; 2020 Nov; 161():105144. PubMed ID: 32810627
[TBL] [Abstract][Full Text] [Related]
20. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
